Psoriasis is a common chronic, non-contagious, immune mediated inflammatory cutaneous disease of diverse clinical manifestations, linked to numerous comorbidities and with a negative impact on a patient’s life. ICD-11 classifies psoriasis under papulosquamous dermatoses, which are categorized as a subtype of inflammatory dermatoses. The etiopathogenesis of the diseases includes genetic, immune, and environmental factors. Plaque psoriasis typically presents with oval or irregular, well demarcated, erythematous, elevated plaques covered with grey-white scales. Distribution of the onset of the disease is bimodal with peaks between 16 and 22 years and between 55 and 60 years. BSA, PASI and DLQI are instruments used to assess the severity of the disease. A therapeutic choice depends on the severity of the disease, localization of lesions, comorbidities, age and gender, pregnancy, other drugs a patient uses and a patient’s preferences. Topical therapy, phototherapy, conventional systemic therapy, and targeted therapy are used in the treatment. A topical psoriasis therapy includes emollients, corticosteroids, vitamin D analogues, calcineurin inhibitors and keratolytics as well as a targeted phototherapy. This is a highly efficient and a very safe therapy applied in a mild disease and as an adjuvant therapy alongside a systemic therapy. The efficacy of topical therapy can be enhanced by combining medicines from different groups. Phototherapy applies the light of a specific wavelength from the spectrum of a visible light or ultraviolent radiation. Phototherapeutic methods include NB-UVB, PUVA, BB-UVB, excimer lasers, PDL etc. Ultraviolet radiation is used in a treatment of stable plaque psoriasis, while lasers are used for smaller localized lesions. A conventional systemic therapy includes primarily ciclosporin A, methotrexate and acitretin. Nowadays, they are being used less due to adverse effects and more effective biologic therapy. Targeted therapy includes therapy with small molecules (apremilast) and biologics. Biologics are complex proteins that target specific molecules involved in the etiopathogenesis of the disease. TNF-α antagonists (etanercept, adalimumab, infliximab, and certolizumab pegol), anti-IL-12/23p40 agent (ustekinumab), anti- IL-17 agents (secukinumab, ixekizumab, and brodalumab), and anti-IL-23p19 agents (guselkumab, tildrakizumab, and risankizumab) are biologics that have been approved in the treatment of psoriasis. Biologics represent a highly effective therapeutic approach in moderate to severe psoriasis. Educating patients, counseling about the cessation of damaging habits and about the importance of weight loss, exercise and healthy diet, sleep improvement, as well as psychological help are also important in the treatment of psoriasis.